
Kluwer Patent Blog

Patent case: The General Hospital Corp. v. Sienna Biopharmaceuticals Inc., USA

Peter Reap (Wolters Kluwer Legal & Regulatory US) · Thursday, May 24th, 2018

In an interference proceeding, the Patent Trial and Appeal Board correctly determined that claims 65-67 of applicant General Hospital Corporation's (GHC's) U.S. Patent Application No. 13/789,575 for methods of removing hair by using nanoparticles to damage hair follicles lacked sufficient written description under § 112 of the Patent Act, the U.S. Court of Appeals for the Federal Circuit has ruled. However, the Board's determination that GHC failed to show that its proposed new claim 74 was patentable and failed to meet its burden of showing that claim 74 interferes with any of the claims of U.S. Patent No. 8,821,941, owned by Sienna Biopharmaceuticals, was arbitrary and capricious. Thus, the Board's denial of GHC's contingent motion to add new claim 74 was vacated and the dispute remanded for further proceedings (*The General Hospital Corp. v. Sienna Biopharmaceuticals, Inc.*, May 4, 2018, Moore, K.).

Case date: 04 May 2018

Case number: No. 2017-1012

Court: United States Court of Appeals, Federal Circuit

A full summary of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Thursday, May 24th, 2018 at 12:02 am and is filed under [Case Law](#), [Pharma](#), [United States of America](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.